Letter to the Editor Regarding "The Role of Combined SGLT1/SGLT2 Inhibition in Reducing the Incidence of Stroke and Myocardial Infarction in Patients with Type 2 Diabetes Mellitus"

Cardiovasc Drugs Ther. 2022 Jun;36(3):571-572. doi: 10.1007/s10557-021-07301-z. Epub 2022 Jan 24.

Authors

Yafei Xie^{1

2}, Xiaowei Zhang^{3

4}

Affiliations

¹ Department of Cardiovascular Medicine, Lanzhou University Second Hospital, Lanzhou, 730000, China.
² Second Clinical Medical College, Lanzhou University, Lanzhou, 730000, China.
³ Department of Cardiovascular Medicine, Lanzhou University Second Hospital, Lanzhou, 730000, China. xwzhang@lzu.edu.cn.
⁴ Second Clinical Medical College, Lanzhou University, Lanzhou, 730000, China. xwzhang@lzu.edu.cn.

PMID: 35067740
DOI: 10.1007/s10557-021-07301-z

No abstract available

Publication types

Letter
Comment

MeSH terms

Diabetes Mellitus, Type 2* / diagnosis
Diabetes Mellitus, Type 2* / drug therapy
Diabetes Mellitus, Type 2* / epidemiology
Humans
Hypoglycemic Agents / adverse effects
Incidence
Myocardial Infarction* / epidemiology
Myocardial Infarction* / prevention & control
Sodium-Glucose Transporter 2
Stroke* / diagnosis
Stroke* / epidemiology
Stroke* / prevention & control

Substances

Hypoglycemic Agents
Sodium-Glucose Transporter 2